Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6849263 | 1.00 | LMNA (0.35) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL2637189 | 1.00 | LMNA (0.35) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL6852245 | 1.00 | LMNA (0.35) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL8671685 | 1.00 | LMNA (0.35) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL864384 | 0.97 | SMN1; SMN2 (0.32) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL338407 | 0.94 | SMN1; SMN2 (0.33) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL2245008 | 0.87 | GAA (0.39) | MEN1KMT2ATSHRCYP4F2CYP4A11 | |
| SCHEMBL2780201 | 0.85 | — | — | |
| SCHEMBL10551402 | 0.84 | LMNA (0.32) | LMNAALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL2095644 | 0.84 | LMNA (0.32) | LMNAALDH1A1HSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108727903-B | Zinc oxide-based nanoparticle ink and quantum dot light-emitting diode | 苏州星烁纳米科技有限公司 | 2021-10-19 | — | — | CN | claimed |
| CN-110938331-A | Zinc oxide nanoparticle ink and electroluminescent device | 苏州星烁纳米科技有限公司 | 2020-03-31 | — | — | CN | claimed |
| CN-107417875-A | One kind has low-surface-energy weather-resisting transparent polyurethane coating and preparation method thereof | 浙江工业大学之江学院 | 2017-12-01 | — | — | CN | claimed |
| US-9427777-B2 | Process for producing charge retention medium | ASAHI GLASS COMPANY, LIMITED (JP) | 2016-08-30 | — | — | US | claimed |
| CN-1455663-A | Novel aerosol formulation containing polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | CN | claimed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| JP-8176090-A | — | — | None | — | — | JP | disclosed |
| EP-4735260-A1 | EPOXY-BASED UV-VIS-CURABLE COMPOSITIONS | Sicpa Holding SA (CH) | 2026-05-06 | — | — | EP | disclosed |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | disclosed |
| EP-4081511-B3 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-20260001838-A1 | NANOMATERIALS | GUIDE THERAPEUTICS LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12449737-B2 | Pattern forming method, resist material, and pattern forming apparatus | Oji Holdings Corporation (JP) | 2025-10-21 | — | — | US | disclosed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
| US-6060626-A | REACTING A FLUORINATED HYDROXY COMPOUND AND A CARBONYL COMPOUND IN PRESENCE OF ETHERIFICATION CATALYST IN HYDROGEN ATOMOSPHERE TO PRODUCE FLUORINE CONTAINING ETHER | KAO CORPORATION (JP) | 2000-05-09 | — | — | US | disclosed |
| US-6046348-A | Silane compound, method for making the same, and electrophotographic photoreceptor | FUJI XEROX CO., LTD. (JP) | 2000-04-04 | — | — | US | disclosed |
| US-6002048-A | Fluorine-containing ether compound and gelling agent containing the same | KAO CORPORATION (JP) | 1999-12-14 | — | — | US | disclosed |
| EP-0837085-A1 | POLYCARBONATE-BASE POLYMER, PRODUCTION PROCESS, RESIN COATING FLUID PREPARED THEREFROM, AND ELECTROPHOTOGRAPHIC PHOTORECEPTOR PREPARED THEREFROM | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1998-04-22 | — | — | EP | disclosed |
| JP-H08176090-A | MONOFUNCTIONAL MONOMER, RESIN COMPOSITION USING THE SAME AND ITS CURED PRODUCT | NIPPON KAYAKU CO LTD | 1996-07-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001838-A1 | NANOMATERIALS | SLC10A1, NPC1L1, FABP1 | LMNA 355/4885ALDH1A1 619/4885HSD17B10 190/4885 |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | LMNA 1950/4885ALDH1A1 339/4885HSD17B10 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.